-
1
-
-
0142017677
-
-
World Health Organization, WHO. Geneva, Switzerland. World Health Organization
-
World Health Organization, WHO. Adherence to long-term therapy: evidence for action. Geneva, Switzerland: World Health Organization, 2003.
-
(2003)
Adherence to Long-term Therapy: Evidence for Action.
-
-
-
2
-
-
20044388168
-
Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)
-
Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005 12: 425 431.
-
(2005)
Eur J Neurol
, vol.12
, pp. 425-431
-
-
Haas, J.1
Firzlaff, M.2
-
3
-
-
0035018884
-
Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject
-
Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001 23: 125 132.
-
(2001)
Ann Behav Med
, vol.23
, pp. 125-132
-
-
Mohr, D.C.1
Boudewyn, A.C.2
Likosky, W.3
Levine, E.4
Goodkin, D.E.5
-
4
-
-
0030332317
-
Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment
-
Mohr DC, Goodkin DE, Likosky W et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 1996 2: 222 226.
-
(1996)
Mult Scler
, vol.2
, pp. 222-226
-
-
Mohr, D.C.1
Goodkin, D.E.2
Likosky, W.3
-
5
-
-
0032438047
-
Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a
-
Mohr DC, Likosky W, Boudewyn AC et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998 4: 487 489.
-
(1998)
Mult Scler
, vol.4
, pp. 487-489
-
-
Mohr, D.C.1
Likosky, W.2
Boudewyn, A.C.3
-
6
-
-
20144382021
-
Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
-
Rio J, Porcel J, Tellez N et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005 11: 306 309.
-
(2005)
Mult Scler
, vol.11
, pp. 306-309
-
-
Rio, J.1
Porcel, J.2
Tellez, N.3
-
7
-
-
0042932742
-
Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS
-
Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003 61: 551 554.
-
(2003)
Neurology
, vol.61
, pp. 551-554
-
-
Tremlett, H.L.1
Oger, J.2
-
9
-
-
0037803726
-
Interferon beta in multiple sclerosis: Experience in a British specialist multiple sclerosis centre
-
Dubois BD, Keenan E, Porter BE et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 2003 74: 946 949.
-
(2003)
J Neurol Neurosurg Psychiatry
, vol.74
, pp. 946-949
-
-
Dubois, B.D.1
Keenan, E.2
Porter, B.E.3
-
10
-
-
13844315516
-
Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns
-
O'rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005 11: 46 50.
-
(2005)
Mult Scler
, vol.11
, pp. 46-50
-
-
O'Rourke, K.E.1
Hutchinson, M.2
-
11
-
-
39749102351
-
Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis
-
Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008 59: 131 135.
-
(2008)
Eur Neurol
, vol.59
, pp. 131-135
-
-
Portaccio, E.1
Zipoli, V.2
Siracusa, G.3
Sorbi, S.4
Amato, M.P.5
-
12
-
-
22144447781
-
Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre
-
Rio J, Tintore M, Nos C, Tellez N, Galan I, Montalban X. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 2005 252: 795 800.
-
(2005)
J Neurol
, vol.252
, pp. 795-800
-
-
Rio, J.1
Tintore, M.2
Nos, C.3
Tellez, N.4
Galan, I.5
Montalban, X.6
-
13
-
-
0347599145
-
Long-term interferon-beta treatment for multiple sclerosis
-
Ruggieri RM, Settipani N, Viviano L et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003 24: 361 364.
-
(2003)
Neurol Sci
, vol.24
, pp. 361-364
-
-
Ruggieri, R.M.1
Settipani, N.2
Viviano, L.3
-
14
-
-
46349110053
-
Adherence to the immunomodulatory drugs for multiple sclerosis: Contrasting factors affect stopping drug and missing doses
-
Tremlett H, Van Der Mei I, Pittas F et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Safety 2008 17: 565 576.
-
(2008)
Pharmacoepidemiol Drug Safety
, vol.17
, pp. 565-576
-
-
Tremlett, H.1
Van Der Mei, I.2
Pittas, F.3
-
16
-
-
0033754825
-
Interferon-beta treatment for patients with multiple sclerosis: The patients' perceptions of the side-effects
-
Gottberg K, Gardulf A, Fredrikson S. Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects. Mult Scler 2000 6: 349 354.
-
(2000)
Mult Scler
, vol.6
, pp. 349-354
-
-
Gottberg, K.1
Gardulf, A.2
Fredrikson, S.3
-
18
-
-
0020686503
-
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
-
Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 13: 227 231.
-
(1983)
Ann Neurol
, vol.13
, pp. 227-231
-
-
Poser, C.M.1
Paty, D.W.2
Scheinberg, L.3
-
19
-
-
0034955141
-
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis
-
Mcdonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 50: 121 127.
-
(2001)
Ann Neurol
, vol.50
, pp. 121-127
-
-
McDonald, W.I.1
Compston, A.2
Edan, G.3
-
20
-
-
0021035886
-
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
-
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33: 1444 1452.
-
(1983)
Neurology
, vol.33
, pp. 1444-1452
-
-
Kurtzke, J.F.1
-
21
-
-
0034727059
-
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
-
Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 343: 898 904.
-
(2000)
N Engl J Med
, vol.343
, pp. 898-904
-
-
Jacobs, L.D.1
Beck, R.W.2
Simon, J.H.3
-
22
-
-
34547497820
-
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study
-
Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 370: 389 397.
-
(2007)
Lancet
, vol.370
, pp. 389-397
-
-
Kappos, L.1
Freedman, M.S.2
Polman, C.H.3
-
23
-
-
33645100122
-
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event
-
Kinkel RP, Kollman C, O'connor P et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006 66: 678 684.
-
(2006)
Neurology
, vol.66
, pp. 678-684
-
-
Kinkel, R.P.1
Kollman, C.2
O'Connor, P.3
-
24
-
-
33244466021
-
Natural history of multiple sclerosis: A unifying concept
-
DOI 10.1093/brain/awl007
-
Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006 129: 606 616. (Pubitemid 43278223)
-
(2006)
Brain
, vol.129
, Issue.3
, pp. 606-616
-
-
Confavreux, C.1
Vukusic, S.2
-
25
-
-
0038149171
-
Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis
-
Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs 2003 35: 163 170.
-
(2003)
J Neurosci Nurs
, vol.35
, pp. 163-170
-
-
Fraser, C.1
Hadjimichael, O.2
Vollmer, T.3
-
26
-
-
54349110518
-
Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm County: A population-based study
-
Gottberg K, Einarsson U, Ytterberg C, Fredrikson S, Von Koch L, Holmqvist LW. Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm County: a population-based study. Mult Scler 2008 14: 962 971.
-
(2008)
Mult Scler
, vol.14
, pp. 962-971
-
-
Gottberg, K.1
Einarsson, U.2
Ytterberg, C.3
Fredrikson, S.4
Von Koch, L.5
Holmqvist, L.W.6
-
27
-
-
33746445987
-
Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis
-
Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006 38: 167 171.
-
(2006)
J Neurosci Nurs
, vol.38
, pp. 167-171
-
-
Cox, D.1
Stone, J.2
-
28
-
-
1842432687
-
Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: A nursing approach
-
Denis L, Namey M, Costello K et al. Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach. J Neurosci Nurs 2004 36: 10 22.
-
(2004)
J Neurosci Nurs
, vol.36
, pp. 10-22
-
-
Denis, L.1
Namey, M.2
Costello, K.3
-
29
-
-
0035525120
-
Adherence to disease-modifying therapy in multiple sclerosis. Part II
-
Holland N, Wiesel P, Cavallo P et al. Adherence to disease-modifying therapy in multiple sclerosis. Part II. Rehabil Nurs 2001 26: 221 226.
-
(2001)
Rehabil Nurs
, vol.26
, pp. 221-226
-
-
Holland, N.1
Wiesel, P.2
Cavallo, P.3
-
30
-
-
0035468790
-
Adherence to disease-modifying therapy in multiple sclerosis: Part i
-
Holland N, Wiesel P, Cavallo P et al. Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehabil Nurs 2001 26: 172 176.
-
(2001)
Rehabil Nurs
, vol.26
, pp. 172-176
-
-
Holland, N.1
Wiesel, P.2
Cavallo, P.3
-
31
-
-
10344225070
-
Strategies for managing the side effects of treatments for multiple sclerosis
-
Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 2004 63: S35 41.
-
(2004)
Neurology
, vol.63
, pp. 35-41
-
-
Langer-Gould, A.1
Moses, H.H.2
Murray, T.J.3
-
32
-
-
25144458103
-
Innovative ways of responding to the information needs of people with MS
-
Maclean R, Russell A. Innovative ways of responding to the information needs of people with MS. Br J Nurs 2005 14: 754 757.
-
(2005)
Br J Nurs
, vol.14
, pp. 754-757
-
-
MacLean, R.1
Russell, A.2
-
33
-
-
0032997515
-
Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis
-
Mohr DC, Goodkin DE, Masuoka L et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler 1999 5: 192 197.
-
(1999)
Mult Scler
, vol.5
, pp. 192-197
-
-
Mohr, D.C.1
Goodkin, D.E.2
Masuoka, L.3
-
35
-
-
27744509228
-
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis
-
Sorensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005 12: 817 827.
-
(2005)
Eur J Neurol
, vol.12
, pp. 817-827
-
-
Sorensen, P.S.1
Deisenhammer, F.2
Duda, P.3
|